Navigation Links
Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting
Date:6/16/2008

SEATTLE, June 16 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced presentation of data at the 2008 Annual European Congress of Rheumatology meeting in Paris demonstrating that repeat administration with TRU-015, Trubion's lead candidate for the treatment of rheumatoid arthritis (RA), continues to produce persistent responses on the American College of Rheumatology (ACR) criteria and consistent pharmacodynamic (PD) effects. In addition, preclinical data presented at the meeting demonstrated that a single dose of SBI-087, a next-generation Small Modular ImmunoPharmaceutical (SMIP(TM)) treatment for RA, resulted in more potent B-cell depletion in peripheral blood and lymphoid tissues than rituximab. Wyeth Pharmaceuticals is developing TRU-015 and SBI-087 in collaboration with Trubion.

Repeated Therapy With TRU-015 Is Well-Tolerated With Consistent PD Profile (OP-0252)

The objective of the ongoing re-treatment study was to evaluate the safety, PD, pharmacokinetics and immunogenicity of TRU-015 for RA with repeated doses after receiving initial administration in a Phase I/IIa study. Patients treated with a single course of 5 mg/kg or higher in a previously conducted TRU-015 Phase I/IIa study were eligible for re-treatment. Patients who received a single infusion of 5 mg/kg received a single infusion of 5 mg/kg upon re-treatment, and those who received higher doses of TRU-015 received a single infusion of 15 mg/kg upon re-treatment. PD response of B-cells was also evaluated after initial treatment and after re-treatment.

Thirty-eight patients have entered the re-treatment study, and re-treatment data were available for 36 patients with some patients having received six courses of TRU-015
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Trubion Announces Presentation of Positive TRU-016 Data at ASCO
2. Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis
3. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
4. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
5. Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkins Lymphoma
6. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
7. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
8. Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
9. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
10. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
11. Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron Pharmaceuticals, ... SAN and NYSE: SNY ) today announced ... in people with hypercholesterolemia met their primary efficacy endpoint ... lipoprotein cholesterol (LDL-C) at 24 weeks compared to placebo ... targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... VEGAS , July 30, 2014  DigiPath, Inc. ... that is expanding into the cannabis testing and education ... in its business and affairs not previously disclosed or, ... the recent unusual market action. "We have ... over the last three trading days," said Steve ...
(Date:7/30/2014)... PHILADELPHIA , July 30, 2014  Packaging Coordinators, ... a definitive agreement to acquire Penn Pharmaceutical Services Limited ... Wales in the United Kingdom ... New Hope, Pennsylvania and Tokyo ... manufacturing services, including Clinical and Commercial dosage form manufacturing, ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8DigiPath No New Corporate Developments 2PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5
... Nov. 10, 2010 SCOLR Pharma, Inc. (NYSE AMEX: ... and nine months ended September 30, 2010.Stephen J. Turner, SCOLR ... of the year will be to continue executing the plans ... which have both been advanced in the last quarter. ...
... Nov. 10, 2010 The Halifax Health - Betty ... celebrated the beginning of a new decade of caring ... during a ceremony held this afternoon in Daytona Beach, ... and Halifax Health will celebrate the 10th anniversary of ...
Cached Medicine Technology:SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results 2SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results 3SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results 4SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results 5SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results 6SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results 7Speediatrics Unit Celebrates 10th Anniversary 2Speediatrics Unit Celebrates 10th Anniversary 3
(Date:7/31/2014)... “Bivalent, Heteronomy and Natural Killer Cells?” opened ... bands ~ homeostatic CS science is the answer.” , ... new on the Bryan William Brickner Blog, ten ... cannabinoid system (CS). The line-up links to PubMed articles ... directly on homeostasis, two each on the central nervous, ...
(Date:7/31/2014)... In its latest blog post, Best ... having family close by during a stay in rehab can ... is successful, is focusing on nine secrets that addicts don’t ... that they can spot an addict from a mile away, ... best Drug Rehabilitation’s CEO Per Wickstrom . “However, take ...
(Date:7/31/2014)... 2014 Continuing Education Company Inc ... Clinical Issues in Primary Care Continuing Medical ... at the Wailea Beach Marriott Resort and Spa on ... been developed for today's Primary Care practitioners. In 5 ... says Barbara Lyons, VP Education. , The agenda for ...
(Date:7/30/2014)... Denver, Colorado (PRWEB) July 30, 2014 ... the skiers wearing orange vests emblazoned with “Blind Skier.” ... Colorado slopes through Foresight Ski Guides , a ... with visually impaired and blind participants (VIPs) for snow ... interested in guiding can learn more and pick up ...
(Date:7/30/2014)... DC (PRWEB) July 31, 2014 ... health care environment more responsive to an increasingly ... years of experience and scholarly expertise to the ... the health care professions: "Diversity and Cultural Competence ... 2013). Janice L. Dreachslin, PhD, a professor in ...
Breaking Medicine News(10 mins):Health News:Homeostatic Cannabinoid Science ~ Publius’ July Roundup on the Bryan William Brickner Blog 2Health News:Latest Best Drug Rehabilitation Blog Posts Focuses on Nine Secrets Addicts Don’t Want Others to Know 2Health News:Latest Best Drug Rehabilitation Blog Posts Focuses on Nine Secrets Addicts Don’t Want Others to Know 3Health News:Clinical Issues in Primary Care Continuing Medical Education (CME) Conference - October 13-17, 2014 in Maui, Hawaii - Agenda Released 2Health News:Clinical Issues in Primary Care Continuing Medical Education (CME) Conference - October 13-17, 2014 in Maui, Hawaii - Agenda Released 3Health News:Colorado Non-Profit Foresight Ski Guides Seeking Applications for Blind and Visually Impaired Skiers and Guides for Vail Ski Season 2Health News:NLN CEO Co-Authors Textbook to Advance Diversity and Cultural Competence Across Health Care Professions 2Health News:NLN CEO Co-Authors Textbook to Advance Diversity and Cultural Competence Across Health Care Professions 3
... Chase, MD Postmenopausal women who have higher testosterone levels ... resistance and the metabolic syndrome compared to women with ... for publication in The Endocrine Society,s Journal of ... is an important step, say researchers, in understanding the ...
... ... and Total Health the all-natural herbal Nutraceutical Company together for the health of our ... ... Association and Registry (ACTHA) announced today that Total Health Enhancement Corp. ...
... ... Scrubs& Beyond shipped directly to their home or work! , ... Brentwood, MO (PRWEB) November 4, 2009 -- Medical professionals ... to their home or work! Orders will ship via SmartPost, which is a collaboration between ...
... Due to the increasing complexities of treating digestive diseases, ... enhanced abilities and experiences in specific disease areas or ... to a "Report of the Multisociety Task Force on ... the achievements of trainees based on specific defined competencies ...
... Nov. 3 Robbins & Myers, Inc. (NYSE: RBN ... Annual Industrial Conference on November 11, 2009. Representing the ... Officer, and Christopher M. Hix, Vice President and Chief Financial ... from 8:20-8:50 a.m., CT, at the Four Seasons Hotel in ...
... of Hematology (ASH) is honoring two prominent hematologists with ASH ... in the training and career development of hematologists early in ... MD, will receive their awards during the 51st ASH Annual ... receiving the Mentor Award for Basic Science, is the David ...
Cached Medicine News:Health News:Postmenopausal women with higher testosterone levels 2Health News:American Competitive Trail Horse Association Announces Total Health Enhancement Corp. as a Sponsor Member 2Health News:Smart Post Brings Scrubs & Beyond to Canadian Doorsteps 2Health News:Gastroenterology/hepatology societies release report evaluating fellowship training curriculum 2Health News:Gastroenterology/hepatology societies release report evaluating fellowship training curriculum 3Health News:The American Society of Hematology to honor inspirational hematologists with Mentor Awards 2